Infratil (ASX: IFT) shares jump 11.7% on CDC’s record 555MW data centre deal

Infratil Ltd (ASX: IFT) shares ripped 11.71% to A$11.73 on Wednesday after its majority-owned data centre business CDC signed a 30-year, 555MW contract with a US investment grade customer, the largest single data centre agreement in Australian history. The deal more than doubles CDC’s contracted capacity to over 1 gigawatt and pushes CDC towards an annualised EBITDAF of roughly A$2 billion once fully deployed. The next confirmed catalyst is Infratil’s FY26 full year result on 26 May 2026, where management guidance, capex funding pathway, and CDC’s revised valuation will be scrutinised line by line.

What does Infratil actually own and why has CDC become the centre of the equity story?

Infratil is a New Zealand listed and ASX listed infrastructure investor with a portfolio that spans renewable generation (Manawa Energy, Mint Renewables, Gurin Energy), Wellington International Airport, diagnostic imaging (Qscan, RHCNZ), telecoms via One NZ, and most significantly CDC Data Centres. Infratil holds a 49.7% economic stake in CDC, alongside Australia’s Future Fund (34.5%), the Commonwealth Superannuation Corporation (12.0%), and CDC management (3.7%).

CDC is no longer a sleeve inside the Infratil portfolio. It is the portfolio. Today’s contract effectively redefines the parent company as a digital infrastructure proxy with airports and renewables attached. The 555MW is roughly 40% of all Australian data centre operating capacity in 2025, signed in a single transaction. CDC also holds Certified Strategic accreditation across all facilities, the only operator in the region with that classification, which is why it sits inside the procurement universe of Australian Federal agencies, defence linked critical infrastructure, and global hyperscalers simultaneously. That sovereign positioning is the moat retail investors should care about.

Who is the US customer and why does the contract structure matter for IFT shareholders?

The customer has not been disclosed. Infratil has confirmed only that it is a US headquartered investment grade entity, which narrows the field to a small number of hyperscalers and AI infrastructure buyers with the credit profile and the capacity needs to absorb 555MW in a single contract. The contract runs 30 years, with renewal options of up to 20 years, and capacity will be delivered across CDC campuses already under construction with first revenue expected to land across FY28 and FY29.

What matters for the equity story is the take-or-pay nature implied by long dated hyperscaler contracts of this scale. Investment grade counterparties signing 30-year terms are not optional commitments. They are bond-like cashflows that get treated by rating agencies as quasi-utility revenue, which is precisely why Moody’s recently assigned CDC its first investment grade rating of Baa2 and S&P assigned Infratil a BBB+ rating earlier in the year. The customer identity will eventually leak or get disclosed, and that reveal is itself a secondary catalyst, but the contract economics do not depend on it.

How does this change CDC’s earnings trajectory between now and FY29?

CDC’s FY27 EBITDAF guidance is unchanged at A$680 million to A$720 million, which is the number that underwrites near term valuation. The step change comes after that. Management now expects FY28 EBITDAF to exceed A$1 billion, roughly 40% to 50% above the FY27 run rate, and an annualised A$2 billion once the full contracted book is operational. That A$2 billion figure is the one driving today’s re-rating, because it implies CDC alone could carry an enterprise value materially larger than Infratil’s entire current market capitalisation of around A$11 billion.

The risk inside that trajectory is execution. CDC expects FY27 capex of A$3.8 billion to A$4.2 billion, excluding land. That is an enormous capital programme for a business currently generating well under A$1 billion in annual EBITDAF. Management has indicated the build will be funded through cash on hand, committed debt facilities, and additional debt and hybrid instruments, with no shareholder equity raise flagged at the parent level. Retail investors should treat that funding mix as the single most important variable to watch into the May 26 result. A clean funding path keeps the equity story intact. A surprise equity raise to top up the build would compress the per-share economics of exactly the contract that drove today’s move.

Why is the broader Australasian data centre thesis suddenly attracting global capital?

Hyperscalers are running into power and land constraints in their primary US markets. Northern Virginia, Phoenix, and the Pacific Northwest are the historic build hubs, but transmission queues, water rights, and community pushback have stretched delivery timelines well beyond what AI workload growth requires. Australasia offers something rare in the current environment: stable sovereign risk, abundant renewable energy generation in development, competitive build costs relative to Singapore or Tokyo, and a regulatory environment that the Australian Government’s National AI Plan has explicitly framed as a digital sovereignty priority.

CDC sits at the intersection of those tailwinds. The company is the only Australasian operator with the certifications, the land bank, the power contracts, and the customer track record to absorb a 555MW commitment without a multi-year qualification cycle. That is why a US investment grade buyer chose CDC over building captive capacity or contracting with a smaller regional player. The thesis for IFT shareholders is that this deal is the first of several rather than the last of its kind, given CDC’s pipeline of operating and planned capacity continues to expand, with the 31 March 2026 independent valuation already up 7.2% in the quarter before today’s announcement.

How is the market currently pricing IFT versus what the newsflow now implies?

Infratil entered today’s session around A$10.45 with a trailing 12-month return of about 2%, lagging the S&P/ASX 200 over the same period. The stock had been range bound between roughly A$9.13 and A$11.43 across the prior year, with sentiment weighed down by valuation concerns flagged by sell side analysts who saw the stock as fully priced ahead of any major contract announcement. Today’s 11.71% move to A$11.73 takes the stock to a fresh 52-week high and breaks the technical range that had defined trading since late 2025.

The pricing question now is whether the market has fully discounted the FY28 EBITDAF step-up or only partially. A 12% one day move on a stock with a A$10 billion market capitalisation implies the market is awarding roughly A$1.2 billion of incremental value to the contract. Given the contract is forecast to add over A$1 billion in annualised EBITDAF at the CDC level, and Infratil’s economic share of that is just under half, the move arguably under-prices the long term value if execution holds. The counter-argument is that CDC’s capex programme introduces real funding and timing risk, and the market is reasonably waiting for the May 26 result before pushing the stock higher.

What are the execution risks retail investors should weigh before getting involved?

The capex bill is the headline risk. A$3.8 billion to A$4.2 billion in FY27 alone is roughly four times the trailing CDC EBITDAF run rate, and the funding mix relies on hybrid instruments and additional debt at a point in the cycle where rates remain elevated. Any tightening of credit conditions or a delay in the hybrid issuance window would force CDC to either slow the build or look upstream to Infratil for equity. Either scenario compresses the IPO-style optionality that has been a long running thesis for IFT holders.

Customer concentration is the second risk. CDC is moving from a diversified contracted book to one where a single US investment grade counterparty represents a substantial share of long-dated revenue. That is normal in hyperscale data centre economics, but it does change the risk profile of the underlying business. The third risk is power. CDC’s renewable power story is central to its sovereign positioning, but Australian transmission infrastructure and grid connection timelines remain genuine bottlenecks for any large-scale build. Delivery across FY28 and FY29 assumes those connections land on schedule.

What are retail investors and forums saying about the IFT setup right now?

The HotCopper IFT thread has historically been quieter than the typical small cap forum, reflecting Infratil’s profile as a large cap infrastructure name held more by superannuation funds than retail traders. Today’s move is changing that dynamic in real time, with attention shifting to whether the breakout above A$11.43 confirms a sustained re-rating or fades back into the prior range ahead of the May 26 result. The Twitter and X cashtag conversation has focused on customer identity speculation, with most commentary cycling through the obvious hyperscaler suspects without concluding.

For investors landing cold from a news alert, the cleaner read is that this is no longer a story about who the customer is. It is a story about whether Infratil can fund the build, deliver the capacity, and translate the contract into the A$2 billion annualised EBITDAF management has put on paper. Those answers come incrementally between now and FY29. The first instalment lands on 26 May 2026.

Key takeaways for retail investors watching IFT

• CDC’s 555MW contract with a US investment grade customer is the largest data centre deal in Australian history and more than doubles CDC’s contracted capacity to over 1GW. The deal is structurally transformative for Infratil’s earnings trajectory.
• Infratil holds a 49.7% economic stake in CDC alongside Australia’s Future Fund and the Commonwealth Superannuation Corporation. CDC is now effectively the dominant value driver inside the IFT portfolio.
• CDC’s FY27 EBITDAF guidance is unchanged at A$680 million to A$720 million. FY28 EBITDAF is expected to exceed A$1 billion, with annualised EBITDAF of roughly A$2 billion once the full contracted capacity is operational.
• The build is capex heavy. CDC expects FY27 capex of A$3.8 billion to A$4.2 billion, funded through cash, debt, and hybrid instruments, with no parent level equity raise flagged.
• The next confirmed catalyst is the Infratil FY26 full year result on 26 May 2026. The CDC valuation update, capex funding detail, and FY27 guidance review will set the tone for the next leg.
• Today’s 11.71% move to A$11.73 is a fresh 52-week high and breaks IFT’s prior trading range. The market is pricing in part of the CDC step-up, with execution risk over FY27 to FY29 the main reason it is not pricing more.
• Customer identity remains undisclosed. The contract economics do not depend on the reveal, but the eventual disclosure is a secondary catalyst worth tracking.